10.25375/uct.12563381.v3 Susan Cleary Susan Cleary Cynthia Tamandjou Tchuem Cynthia Tamandjou Tchuem geetesh solanki geetesh solanki Sumaiyah Docrat Sumaiyah Docrat Donela Besada Donela Besada Tommy Wilkinson Tommy Wilkinson MOSAIC: A model to assess the cost-effectiveness of dexamethasone for admitted COVID-19 patients in South Africa University of Cape Town 2020 COVID-19 Covid-19 COVID-19 data SARS-CoV-2 dexamethasone economic evaluation Cost effectiveness Model Severe Acute Respiratory Syndrome Coronavirus HCoV-19 2019-nCov Health Economics 2020-07-23 07:20:07 Dataset https://zivahub.uct.ac.za/articles/dataset/MOSAIC_A_model_to_assess_the_cost-effectiveness_of_dexamethasone_for_admitted_COVID-19_patients_in_South_Africa/12563381 <table><tr><td>MODEL STRATEGIES</td></tr><tr><td>This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death.</td></tr><tr><td><br>Two competing strategies are modelled:</td></tr><tr><td>1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone).</td></tr><tr><td>2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days.</td></tr><tr><td> <br></td></tr><tr><td>MODEL OUTCOMES</td></tr><tr><td>Cost: mean cost (general ward and ICU) per admitted patient from the health care provider's perspective.</td></tr><tr><td>Health outcomes: mean DALYs and deaths per admitted patient. </td></tr><tr><td>Other: mean ICU days and inpatient days per admitted patient.</td></tr></table>